87 results on '"Iikuni, N"'
Search Results
2. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
3. Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese
4. Low disease activity state with corticosteroid may not represent ‘true’ low disease activity state in patients with rheumatoid arthritis
5. Pain reduction in patients with rheumatoid arthritis receiving tofacitinib monotherapy with or without pain medication: A post hoc analysis of pooled data from phase 2, phase 3 and phase 3B/4 studies
6. What's in season for rheumatoid arthritis patients? Seasonal fluctuations in disease activity
7. Soluble fractalkine in the cerebrospinal fluid of patients with neuropsychiatric lupus
8. Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis
9. IP-10/MCP-1 ratio in CSF is an useful diagnostic marker of neuropsychiatric lupus patients
10. Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus
11. Single nucleotide polymorphisms in the gene encoding the major histocompatibility complex class II transactivator (CIITA) in systemic lupus erythematosus
12. SAT0252 Clinical and functional response to tofacitinib and adalimumab in patients with rheumatoid arthritis: probability plot analysis of results from the oral strategy trial
13. SAT0247 Impact of glucocorticoids on efficacy and safety of tofacitinib with and without methotrexate and adalimumab with methotrexate for rheumatoid arthritis: results from a phase 3b/4 randomised trial
14. SAT0256 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: patient-reported outcomes from a phase 3b/4 randomised trial
15. SAT0220 Evaluation of live zoster vaccine in a subset of patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, and adalimumab with methotrexate: results from a phase 3b/4 randomised trial
16. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
17. OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials: Table 1
18. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus--the Hopkins Lupus Cohort
19. Patient-reported fatigue and its impact on patients with systemic lupus erythematosus
20. Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin
21. Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese
22. Low disease activity state with corticosteroid may not represent 'true' low disease activity state in patients with rheumatoid arthritis
23. MHC2TA is associated with rheumatoid arthritis in Japanese patients
24. IP-10/MCP-1 ratio in CSF is an useful diagnostic marker of neuropsychiatric lupus patients
25. Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis
26. Patient-reported fatigue and its impact on patients with systemic lupus erythematosus.
27. Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study.
28. Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice
29. Leptin and Inflammation
30. Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis.
31. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
32. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
33. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
34. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
35. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial.
36. Leptin enhances availability of apoptotic cell-derived self-antigen in systemic lupus erythematosus.
37. Regulatory CD4+ T cells promote B cell anergy in murine lupus.
38. Leptin promotes lupus T-cell autoimmunity.
39. Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance.
40. Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity.
41. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.
42. Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus.
43. Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice.
44. Antibody-based therapies in systemic lupus erythematosus.
45. The influence of sex on patients with rheumatoid arthritis in a large observational cohort.
46. Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus.
47. Leptin and Inflammation.
48. MHC2TA is associated with rheumatoid arthritis in Japanese patients.
49. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM).
50. ITGAV polymorphism and disease susceptibility in a Japanese rheumatoid arthritis population.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.